Daclizumab: a novel therapeutic option in severe bullous pemphigoid.

摘要: A 52-year-old woman with a body weight of 102 kg presented widespread multiple blisters and bullae on the whole before hospitalization. Clinical features conventional histopathology confirmed diagnosis BP; immunohistology immunoserological tests were performed compatible BP. The patient was subsequently treated prednisolone 100 mg/day in combination azathioprine mg/day, cyclosporin 200 mg mycophenolate mofetil 2 g/day. However, disease control not achieved blister formation progressed. During steroid therapy gained 35 developed diabetes mellitus glucose levels around 180 mg/dl. Therefore, dosage reduced slowly to 5 maintained bolus intravenous infusion (approximately 1 mg/kg weight) daclizumab (ZenapaxH) given fortnightly. Azathioprine treatment 50 continued steroids reduced. In total, received six infusions during hospitalization as day-care centre. prednisolone, well tolerated no side effects observed or after treatment. Pathological normalized lost weight. An improvement condition skin within weeks daclizumab. completely resolved postinflammatory hyperpigmentation remained residual effect. resolution persisted for approximately 3 months, new occurred despite prednisolone. second series three (100 mg/day) administered every 3–4 weeks. responded rapidly has free lesions more than 10 months so far.